S, et al. Treatment of men for “low testosterone”: a systematic review. PLoS One. 2016;11(9):e0162480. https://pubmed.ncbi.nlm.nih.gov/27655114/

4354

Kohn TP, Mata DA, Ramasamy R, Lipshultz LI. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol. 2016;69(6):1083–90. https://pubmed.ncbi.nlm.nih.gov/26874809/

4355

Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293–7. https://pubmed.ncbi.nlm.nih.gov/12050481/

4356

Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007;9(Suppl 1):S3–8. https://pubmed.ncbi.nlm.nih.gov/17387371/

4357

Miner M, Barkin J, Rosenberg MT. Testosterone deficiency: myth, facts, and controversy. Can J Urol. 2014;21(Suppl 2):39–54. https://pubmed.ncbi.nlm.nih.gov/24978631/

4358

Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349(4):366–81. https://pubmed.ncbi.nlm.nih.gov/12878745/

4359

Salter CA, Mulhall JP. Guideline of guidelines: testosterone therapy for testosterone deficiency. BJU Int. 2019;124(5):722–9. https://pubmed.ncbi.nlm.nih.gov/31420972/

4360

Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349(4):366–81. https://pubmed.ncbi.nlm.nih.gov/12878745/

4361

Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901–13. https://pubmed.ncbi.nlm.nih.gov/29801017/

4362

Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374–83. https://pubmed.ncbi.nlm.nih.gov/19276453/

4363

Division of Cancer Prevention and Control, Centers for Disease Control and Prevention. Prostate cancer statistics. CDC.gov. http://www.cdc.gov/cancer/prostate/statistics/index.htm. Updated September 2, 2014. Accessed May 15, 2022.; https://www.cdc.gov/cancer/prostate/statistics/index.htm

4364

Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901–13. https://pubmed.ncbi.nlm.nih.gov/29801017/

4365

Moyer VA, LeFevre ML, Sui AL, et al. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–34. https://pubmed.ncbi.nlm.nih.gov/22801674/

4366

Livingston CJ, Freeman RJ, Mohammad A, et al. Choosing Wisely® in preventive medicine. Am J Prev Med. 2016;51(1):141–9. https://pubmed.ncbi.nlm.nih.gov/27155735/

4367

Mulhem E, Fulbright N, Duncan N. Prostate cancer screening. Am Fam Physician. 2015;92(8):683–8. https://pubmed.ncbi.nlm.nih.gov/26554408/

4368

Ivlev I, Jerabkova S, Mishra M, Cook LA, Eden KB. Prostate cancer screening patient decision aids: a systematic review and meta-analysis. Am J Prev Med. 2018;55(6):896–907. https://pubmed.ncbi.nlm.nih.gov/30337235/

4369

Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901–13. https://pubmed.ncbi.nlm.nih.gov/29801017/

4370

Carter HB. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. BJU Int. 2013;112(5):543–7. https://pubmed.ncbi.nlm.nih.gov/23924423/

4371

Wilt TJ, Harris RP, Qaseem A, et al. Screening for cancer: advice for high-value care from the American College of Physicians. Ann Intern Med. 2015;162(10):718–25. https://pubmed.ncbi.nlm.nih.gov/25984846/

4372

American Cancer Society recommendations for prostate cancer early detection. American Cancer Society. https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/acs-recommendations.html. Updated April 23, 2021. Accessed May 5, 2022.; https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/acs-recommendations.html

4373

Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901–13. https://pubmed.ncbi.nlm.nih.gov/29801017/

4374

Tikkinen KAO, Dahm P, Lytvyn L, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. BMJ. 2018;362:k3581. https://pubmed.ncbi.nlm.nih.gov/30185545/

4375

Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J Natl Cancer Inst. 2009;101(17):1216–20. https://pubmed.ncbi.nlm.nih.gov/19671770/

4376

Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901–13. https://pubmed.ncbi.nlm.nih.gov/29801017/

4377

Tikkinen KAO, Dahm P, Lytvyn L, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. BMJ. 2018;362:k3581. https://pubmed.ncbi.nlm.nih.gov/30185545/

4378

Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901–13. https://pubmed.ncbi.nlm.nih.gov/29801017/

4379

Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901–13. https://pubmed.ncbi.nlm.nih.gov/29801017/

4380

Early detection of prostate cancer. Harding Center for Risk Literacy. https://www.hardingcenter.de/sites/default/files/2021–11/fact%20%20box_PSA_EN_new_design_20201123_final.pdf. Updated November 2020. Accessed May 4, 2022.; https://www.hardingcenter.de/en/transfer-and-impact/fact-boxes/early-detection-of-cancer/early-detection-of-prostate-cancer-with-psa-testing

4381

Early detection of prostate cancer. Harding Center for Risk Literacy. https://www.hardingcenter.de/sites/default/files/2021–11/fact%20%20box_PSA_EN_new_design_20201123_final.pdf. Updated November 2020. Accessed May 4, 2022.; https://www.hardingcenter.de/en/transfer-and-impact/fact-boxes/early-detection-of-cancer/early-detection-of-prostate-cancer-with-psa-testing

4382

Our History. Endocrine Society. https://www.endocrine.org/our-community/advancing-endocrinology-and-public-health/history. Accessed May 5, 2022.; https://www.endocrine.org/our-community/advancing-endocrinology-and-public-health/history

4383

Al-Sharefi A, Quinton R. Current national and international guidelines for the management of male hypogonadism: helping clinicians to navigate variation in diagnostic criteria and treatment recommendations. Endocrinol Metab (Seoul). 2020;35(3):526–40. https://pubmed.ncbi.nlm.nih.gov/32981295/

4384

Swee DS, Gan EH. Late-onset hypogonadism as primary testicular failure. Front Endocrinol (Lausanne). 2019;10:372. https://pubmed.ncbi.nlm.nih.gov/31244778/

4385

Rastrelli G, Carter EL, Ahern T, et al. Development of and recovery from secondary hypogonadism in aging men: prospective results from the EMAS. J Clin Endocrinol Metab. 2015;100(8):3172–82. https://pubmed.ncbi.nlm.nih.gov/26000545/

4386

Davidson LM, Millar K, Jones C, Fatum M, Coward K. Deleterious effects of obesity upon the hormonal and molecular mechanisms controlling spermatogenesis and male fertility. Hum Fertil (Camb). 2015;18(3):184–93. https://pubmed.ncbi.nlm.nih.gov/26205254/

4387

Camacho EM, Huhtaniemi IT, O’Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the